Tetra Bio-Pharma Provides Update on Patent Applications for Novel Therapeutic ARDS-003

• Tetra strengthens its intellectual property position with PCT and provisional patent applications for its innovative therapeutic, ARDS-003.

MONTREAL, Nov. 29, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today announced the filing of three patent applications for its novel therapeutic, ARDS-003.

1. The Company filed an international patent under PCT (Patent Cooperation Treaty) related to the methodology, including improvements, for the synthesis of target synthetic cannabinoid derivatives, specifically HU308 (known as Onternabez) and HU433. (Methods, Processes, and Compositions for Improved Preparation of HU308 and HU433 Application No. PCT/CA2021/051327)
2. The Company filed an international PCT application related to the pharmaceutical methods of production and uses of the compositions comprising Onternabez, suitable for parenteral delivery. (Parenteral Cannabinoid Formulations and Uses Thereof Application No. PCT/CA2021/051882).
3. The Company filed a provisional patent application with the United States Patent and Trademark Office related to crystalline Onternabez and uses thereof. This application covers identification of novel polymorphs and cocrystals of Onternabez, which will allow for extended patent protection on Onternabez and may lead to improvements in stability and solubility when formulating Onternabez for future drug products.

Guy Chamberland, CEO and Chief Regulatory Officer at Tetra commented “This is a significant step in protecting our novel therapeutic, ARDS-003. It is especially significant, considering the potential use of this novel cannabinoid molecule in antiviral and immunomodulator therapies. These patents would be enforceable once granted and provide additional protection to investors for up to 20 years from the filing date.”

These three patent applications become part of Tetra’s growing IP portfolio, which includes, 14 granted/issued patents, as well as one (1) provisional and five (5) PCT applications pending across international and national jurisdictions.

ARDS-003 is a novel First in Human (FIH) drug product containing the active pharmaceutical agent, Onternabez, a potent and selective full agonist of the type 2 cannabinoid receptor (CB2R), an essential immunomodulatory target. ARDS-003 is positioned to modulate acute systemic inflammation and prevent sepsis, ARDS, and organ damage. While the clinical profile of ARDS arising from viral (COVID) or bacterial sepsis can vary, hyperinflammation involving a dysfunctional immune response is a common mediator of lung damage. Tetra’s pre-clinical studies have demonstrated that ARDS-003 decreases this hyperinflammatory response and slows disease progression.

Tetra Bio-Pharma (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Their evidence-based scientific approach has enabled them to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. With patients at the core of what they do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing biopharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the success of this product or any other product, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

View original content to download multimedia:https://www.prnewswire.com/news-releases/tetra-bio-pharma-provides-update-on-patent-applications-for-novel-therapeutic-ards-003-301688342.html

SOURCE Tetra Bio-Pharma Inc.